PE20020277A1 - POLIMORFO 1-{6-ETOXI-5-[3-ETIL-6,7-DIHIDRO-2-(2-METOXIETIL)-7-OXO-2H-PIRAZOLO[4,3-d]PIRIMIDIN-5-IL]-3-PIRIDILSULFONIL}-4-ETILPIPERAZINA - Google Patents

POLIMORFO 1-{6-ETOXI-5-[3-ETIL-6,7-DIHIDRO-2-(2-METOXIETIL)-7-OXO-2H-PIRAZOLO[4,3-d]PIRIMIDIN-5-IL]-3-PIRIDILSULFONIL}-4-ETILPIPERAZINA

Info

Publication number
PE20020277A1
PE20020277A1 PE2001000746A PE2001000746A PE20020277A1 PE 20020277 A1 PE20020277 A1 PE 20020277A1 PE 2001000746 A PE2001000746 A PE 2001000746A PE 2001000746 A PE2001000746 A PE 2001000746A PE 20020277 A1 PE20020277 A1 PE 20020277A1
Authority
PE
Peru
Prior art keywords
metoxyethyl
ethylpiperazine
polymorph
pyrazolo
pyrimidin
Prior art date
Application number
PE2001000746A
Other languages
English (en)
Spanish (es)
Inventor
Laurence James Harris
Richard Anthony Storey
Albert Shaw Wood
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0018656A external-priority patent/GB0018656D0/en
Priority claimed from GB0106464A external-priority patent/GB0106464D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of PE20020277A1 publication Critical patent/PE20020277A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
PE2001000746A 2000-07-28 2001-07-24 POLIMORFO 1-{6-ETOXI-5-[3-ETIL-6,7-DIHIDRO-2-(2-METOXIETIL)-7-OXO-2H-PIRAZOLO[4,3-d]PIRIMIDIN-5-IL]-3-PIRIDILSULFONIL}-4-ETILPIPERAZINA PE20020277A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0018656A GB0018656D0 (en) 2000-07-28 2000-07-28 Pharmaceutically active compounds
GB0106464A GB0106464D0 (en) 2001-03-15 2001-03-15 Crystalline therapeutic agent

Publications (1)

Publication Number Publication Date
PE20020277A1 true PE20020277A1 (es) 2002-05-11

Family

ID=26244756

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000746A PE20020277A1 (es) 2000-07-28 2001-07-24 POLIMORFO 1-{6-ETOXI-5-[3-ETIL-6,7-DIHIDRO-2-(2-METOXIETIL)-7-OXO-2H-PIRAZOLO[4,3-d]PIRIMIDIN-5-IL]-3-PIRIDILSULFONIL}-4-ETILPIPERAZINA

Country Status (45)

Country Link
EP (1) EP1305314B1 (enExample)
JP (1) JP2004505087A (enExample)
KR (1) KR100457937B1 (enExample)
CN (1) CN1207297C (enExample)
AP (1) AP1400A (enExample)
AR (1) AR032628A1 (enExample)
AT (1) ATE286901T1 (enExample)
AU (2) AU7269001A (enExample)
BG (1) BG107266A (enExample)
BR (1) BR0112734A (enExample)
CA (1) CA2417264C (enExample)
CZ (1) CZ2003126A3 (enExample)
DE (1) DE60108398T2 (enExample)
DO (1) DOP2001000217A (enExample)
DZ (1) DZ3364A1 (enExample)
EA (1) EA004681B1 (enExample)
EC (1) ECSP034454A (enExample)
EE (1) EE200300045A (enExample)
ES (1) ES2231521T3 (enExample)
GE (1) GEP20053494B (enExample)
HR (1) HRP20030061A2 (enExample)
HU (1) HUP0302982A3 (enExample)
IL (1) IL153226A0 (enExample)
IN (1) IN2002MU01649A (enExample)
IS (1) IS6626A (enExample)
MA (1) MA26931A1 (enExample)
MX (1) MX233602B (enExample)
MY (1) MY117831A (enExample)
NO (1) NO324220B1 (enExample)
NZ (1) NZ523226A (enExample)
OA (1) OA12337A (enExample)
PA (1) PA8523501A1 (enExample)
PE (1) PE20020277A1 (enExample)
PH (1) PH12001001922B1 (enExample)
PL (1) PL365133A1 (enExample)
PT (1) PT1305314E (enExample)
SK (1) SK572003A3 (enExample)
SV (1) SV2001000570A (enExample)
TN (1) TNSN01112A1 (enExample)
TW (1) TWI285643B (enExample)
UA (1) UA72631C2 (enExample)
UY (1) UY26854A1 (enExample)
WO (1) WO2002010171A1 (enExample)
YU (1) YU4703A (enExample)
ZA (1) ZA200301457B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004072079A1 (en) * 2003-02-11 2004-08-26 Pfizer Limited Hydrated and anhydrous sildenafil hemi-citrate compound
MXPA05011643A (es) 2003-04-29 2005-12-15 Pfizer Ltd 5,7-diaminopirazolo[4,3-d]pirimidinas en el tratamiento de hipertension.
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
WO2005097799A1 (en) 2004-04-07 2005-10-20 Pfizer Limited Pyrazolo`4,3-d! pyrimidines
CA2608018C (en) 2005-05-12 2010-07-13 Pfizer Inc. Anhydrous crystalline forms of n-[1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1134442C (zh) * 1998-04-20 2004-01-14 美国辉瑞有限公司 吡唑并嘧啶酮cGMP PDE5抑制剂、其制备方法及用途及中间体
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them

Also Published As

Publication number Publication date
NZ523226A (en) 2003-07-25
ATE286901T1 (de) 2005-01-15
YU4703A (sh) 2006-01-16
EP1305314A1 (en) 2003-05-02
SK572003A3 (en) 2004-05-04
EE200300045A (et) 2004-12-15
GEP20053494B (en) 2005-04-25
SV2001000570A (es) 2002-09-03
PT1305314E (pt) 2005-04-29
PL365133A1 (en) 2004-12-27
OA12337A (en) 2006-05-15
AP1400A (en) 2005-04-28
IL153226A0 (en) 2003-07-06
EA200300079A1 (ru) 2003-06-26
CZ2003126A3 (cs) 2004-02-18
HRP20030061A2 (en) 2003-04-30
UA72631C2 (uk) 2005-03-15
NO20030416L (no) 2003-02-05
HK1055954A1 (en) 2004-01-30
MY117831A (en) 2004-08-30
PA8523501A1 (es) 2002-10-24
KR20030016430A (ko) 2003-02-26
BG107266A (bg) 2003-07-31
ES2231521T3 (es) 2005-05-16
TNSN01112A1 (fr) 2005-11-10
WO2002010171A1 (en) 2002-02-07
MX233602B (es) 2006-01-10
CA2417264A1 (en) 2002-02-07
CN1444585A (zh) 2003-09-24
ECSP034454A (es) 2003-03-10
AU7269001A (en) 2002-02-13
UY26854A1 (es) 2002-02-28
EP1305314B1 (en) 2005-01-12
MXPA03000856A (es) 2003-06-06
CN1207297C (zh) 2005-06-22
HUP0302982A2 (hu) 2003-12-29
DE60108398D1 (de) 2005-02-17
NO324220B1 (no) 2007-09-10
TWI285643B (en) 2007-08-21
DE60108398T2 (de) 2005-12-22
DOP2001000217A (es) 2002-10-30
PH12001001922B1 (en) 2006-11-21
ZA200301457B (en) 2004-04-28
JP2004505087A (ja) 2004-02-19
NO20030416D0 (no) 2003-01-27
IN2002MU01649A (enExample) 2004-12-11
AR032628A1 (es) 2003-11-19
BR0112734A (pt) 2004-08-10
AP2001002234A0 (en) 2001-09-30
MA26931A1 (fr) 2004-12-20
IS6626A (is) 2002-11-18
DZ3364A1 (fr) 2002-02-07
KR100457937B1 (ko) 2004-11-20
CA2417264C (en) 2007-06-12
HUP0302982A3 (en) 2005-01-28
EA004681B1 (ru) 2004-06-24
AU2001272690B2 (en) 2005-12-08

Similar Documents

Publication Publication Date Title
EA200100369A1 (ru) Химиотерапия рака с помощью ацетилдиналина в комбинации с гемцитабином, кэйпцитабином или цис-платиной
NO995893L (no) Elektrisk drivanordning for undervanns hydrauliske brønnhodeverktøy
AR022593A1 (es) Un metodo para efectuar el blanqueado realzado de los dientes
IT8420895A0 (it) Anello di protezione per linee ditrasmissione di energia.
EA200500017A1 (ru) Новые соединения
DE69529998D1 (de) Glp-1 zusammensetzungen mit verlängerter wirkdauer
MX219947B (enExample)
DE69835773D1 (de) Wasserverträgliche energie-härtbare zusammensetzungen, die maleimidderivate enthalten
ES2191393T3 (es) Nuevos pigmentos de complejos metalicos.
DK0700380T3 (da) N-Alkylthiopolyaminderivater som radioprotektive midler
ES2179476T3 (es) Procedimiento para preparar derivados de pirazol.
PE20020277A1 (es) POLIMORFO 1-{6-ETOXI-5-[3-ETIL-6,7-DIHIDRO-2-(2-METOXIETIL)-7-OXO-2H-PIRAZOLO[4,3-d]PIRIMIDIN-5-IL]-3-PIRIDILSULFONIL}-4-ETILPIPERAZINA
EA200200545A1 (ru) Онколитические комбинации для лечения рака
DE59902827D1 (de) Azidfreie, gaserzeugende Zusammensetzung
FR2677500B1 (fr) Laser raman.
EA200100852A1 (ru) Производные резорцина
ITRC980008A0 (it) Impianto a "pozzo" per lo sfruttamento dell'energia delle onde del mare.
AU2003272641A1 (en) Focused radiation visualization
IT1293777B1 (it) Processo per la preparazione di tetraazamacrocicli
FR2791053B1 (fr) Composition composite comprenant du percarbonate de sodium ayant une solubilite amelioree
BG101221A (bg) N-заместени азабициклохептанови производни, приложими като невролептици
EA200201023A1 (ru) Ингибитор натрий-водородного обмена типа 1(nhe-1)
NO20004366L (no) Pakning for energibronner
DE69829312D1 (de) Intensive, kohärente hochfrequenzstrahlungsquelle
RU2000103198A (ru) Окта-4,5-карбоксифталоцианины как фотосенсибилизаторы для фотодинамической терапии

Legal Events

Date Code Title Description
FC Refusal